Amicus Therapeutics FOLD announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback